Mitoquinone mesylate (Mitoquinone methanesulfonate) |
| Catalog No.GC31292 |
Mitoquinone mesylate (Mitoquinone methanesulfonate) is among the widely used antioxidants that target the mitochondria.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 845959-50-4
Sample solution is provided at 25 µL, 10mM.
Mitoquinone mesylate (Mitoquinone methanesulfonate) is among the widely used antioxidants that target the mitochondria. It was developed to readily penetrate the BBB and neuronal membranes, where it is concentrated into several hundred-folds within the mitochondria where it mediates the local anti-oxidative capacity [1]. Within the ETC, complex II, also known as succinate dehydrogenase, reduces Mitoquinone mesylate ubiquinone moiety to the active antioxidant ubiquinol which scavenges excess ROS [2].
Mitoquinone mesylate (50 nM) reduced 6-OHDA-induced mitochondrial fragmentation, when used in SH-SY5Y cell line. It inhibited mitochondrial fission protein and the translocation of pro-apoptotic protein (Bax) in the mitochondria [3].
Mitoquinone mesylate treatment inhibited the loss of dopaminergic neurons and enhanced behavioral performance, showed neuroprotective effects in mouse models of PD [4]. Mitoquinone mesylate treatment enhanced the fine motor control and reduced markers of oxidative damage in muscles in a Huntington's disease (HD) mouse model [5]. Mitoquinone mesylate reduced white matter injury, improved neurological performance, and decreased motor-evoked potential latency in intracerebral hemorrhagic (ICH) mice [6].
References:
[1]. Murphy M P, Smith R A J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations[J]. Annu. Rev. Pharmacol. Toxicol., 2007, 47: 629-656.
[2]. James A M, CochemÉ H M, Smith R A J, et al. Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species: IMPLICATIONS FOR THE USE OF EXOGENOUS UBIQUINONES AS THERAPIES AND EXPERIMENTAL TOOLS*♦[J]. Journal of Biological Chemistry, 2005, 280(22): 21295-21312.
[3]. Solesio M E, Prime T A, Logan A, et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2013, 1832(1): 174-182.
[4]. Pinho B R, Duarte A I, Canas P M, et al. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice[J]. Free Radical Biology and Medicine, 2020, 146: 372-382.
[5]. Pinho B R, Duarte A I, Canas P M, et al. The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice[J]. Free Radical Biology and Medicine, 2020, 146: 372-382.
[6]. Chen W, Guo C, Jia Z, et al. Inhibition of mitochondrial ROS by MitoQ alleviates white matter injury and improves outcomes after intracerebral haemorrhage in mice[J]. Oxidative medicine and cellular longevity, 2020, 2020.
| Cell experiment [1]: | |
Cell lines | HSC-T6 cells |
Preparation Method | Mitoquinone mesylate was added directly to the culture medium at final concentrations of 2 µM, 20 µM, 13 µM, 50 nM, or 10 µM, respectively, for 24 h. |
Reaction Conditions | 2 µM, 20 µM, 13 µM, 50 nM, or 10 µM for 24 hours |
Applications | Confocal fluorescence microscopy showed that mitoquinone mesylate treatment reversed fragmented mitochondria in active HSCs to an elongated state. Immunoblot analysis showed significantly downregulated Fis1 and Drp1 after mitoquinone mesylate treatment. |
| Animal experiment [2]: | |
Animal models | male Wistar rats |
Preparation Method | For pharmacokinetic study, groups of rats (n = 4-5) were administered either an intravenous (IV) dose (5 mg/kg) via the cannula or an oral dose (25 mg/kg) by gavage. |
Dosage form | Intravenous injection, 5 mg/kg; oral, 25 mg/kg. |
Applications | After oral administration, mitoquinone mesylate was rapidly absorbed giving a plasma concentration of about 25 ng/mL after about 1 h. Thereafter, mitoquinone mesylate concentration fluctuated reaching a maximum (Cmax) of 31.2 ± 6.9 ng/mL at 4.0 h. After IV administration, the plasma concentration of mitoquinone mesylate exhibited an exponential decline with a rapid distribution phase followed by a slower elimination phase |
References: | |
| Cas No. | 845959-50-4 | SDF | |
| Canonical SMILES | [O-]S(=O)(C)=O.O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O | ||
| Formula | C38H47O7PS | M.Wt | 678.81 |
| Solubility | DMSO : 50 mg/mL (73.66 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4732 mL | 7.3658 mL | 14.7317 mL |
| 5 mM | 294.6 μL | 1.4732 mL | 2.9463 mL |
| 10 mM | 147.3 μL | 736.6 μL | 1.4732 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
MitoQ attenuated NLRP3-inflammasome activation and apoptosis in AlCl3-treated Parkin-/- mice hippocampus. (C) Effects of MitoQ on the apoptosis of mice hippocampus by TUNEL staining. The histogram represents the ratio of TUNEL-positive cells.
The second-time was treated with normal saline, MitoQ (5mg/kg body weight, twice weekly，GLPBIO, USA) or MCC950 by intraperitoneal injection in the afternoon of the same day.
Ecotox Environ Safe, 2023, 264: 115459. PMID: 37703808 IF: 6.7996 -
Related Biological Data
MitoQ alleviated mtROS overproduction, activation of NLRP3-inflammasome and W/β signaling, fibrosis and structural and functional damage in the T-2 animal model. (F, G) Protein levels of NLRP3, pro-IL-1β, and caspase-1 p20 in mice kidneys.
MitoQ (100μM, GLPBIO, USA), MCC950 (10μM), or ICG-001 (10μM) were added to the culture medium for 4h before exposing to T-2 media.
J Agr Food Chem (2022). PMID: 36239691 IF: 5.8954 -
Related Biological Data
(J) TUNEL staining of apoptosis.
The MitoQ (GLPBIO, USA) was intraperitoneally administered to mice in HFPO-TA + MitoQ group (5mg/kg, twice/week for 4 weeks).
Food Chem Toxicol (2023): 113706. PMID: 36871880 IF: 5.5716 -
Related Biological Data
ApoE4 exacerbates oxidative stress after oxyHb or SAH. (N-R) Western blots bands (N) of CD16, CD86, Arg-1 and CD206 in APOE4-PBS and APOE4-mitoQ, densitometric quantification of CD16 (O), CD86 (P), Arg-1 (Q) and CD206 (R).
Mitoquinone (GLPBIO, USA) was prepared by dissolving 5mg in dimethylsulfoxide (DMSO).
Neuroscience, 2023. PMID: 37290684 IF: 3.708
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *